X4 Pharmaceuticals

OverviewSuggest Edit

X4 Pharmaceuticals is a clinical-stage oncology company, which develops oral small molecule CXCR4 antagonists for the treatment of refractory solid tumors. It focuses on developing X4P-001, a drug candidate for refractory clear cell renal cell carcinoma and refractory epithelial ovarian cancer; and X4P-002, a series of late lead molecules that penetrate the blood brain barrier.

TypePrivate
Founded2012
HQCambridge, MA, US
Websitex4pharma.com

Latest Updates

Employees (est.) (Jul 2021)80(+3%)
Job Openings3
Cybersecurity ratingBMore

Key People/Management at X4 Pharmaceuticals

Paula Ragan

Paula Ragan

CEO and President
Adam Mostafa

Adam Mostafa

Chief Financial Officer
Art Taveras

Art Taveras

Chief Scientific Officer
Diego Cadavid

Diego Cadavid

Chief Medical Officer
Mary Dibiase

Mary Dibiase

Vice President, Technical Operations and Quality
Derek Meisner

Derek Meisner

General Counsel
Show more

X4 Pharmaceuticals Office Locations

X4 Pharmaceuticals has offices in Cambridge and Wien
Cambridge, MA, US (HQ)
955 Massachusetts Ave
Wien, AT
Helmut-Qualtinger-Gasse 2
Show all (2)

X4 Pharmaceuticals Financials and Metrics

Summary Metrics

Founding Date

2012

X4 Pharmaceuticals total Funding

$64.5 m

X4 Pharmaceuticals latest funding size

$27 m

Time since last funding

4 years ago

X4 Pharmaceuticals investors

X4 Pharmaceuticals's latest funding round in November 2017 was reported to be $27 m. In total, X4 Pharmaceuticals has raised $64.5 m
Show all financial metrics

X4 Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

X4 Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

X4 Pharmaceuticals Online and Social Media Presence

Embed Graph

X4 Pharmaceuticals News and Updates

X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia at EHA 2021

Robust decreases in serum IgM at low- and mid-doses suggest best-in-class potential for mavorixafor plus ibrutinib therapy in double-mutation Waldenström’s patients; meaningful increases in hemoglobin levels suggest reduction in cancer burden in bone marrow

X4 Pharmaceuticals to Host Conference Call and Webcast to Present Initial Efficacy and Safety Data from EHA 2021 Poster on Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia

Poster presentation by lead author Dr. Steven Treon available on the EHA website Friday, June 11, 2021 at 9:00 am CET/3:00 am ET

X4 Pharmaceuticals Announces Positive Preliminary Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia as Published in EHA Abstract

Initial data from first cohort of patients indicate mavorixafor plus ibrutinib to be well tolerated, with encouraging decreases in serum IgM observed

X4 Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update

Company continues to make significant clinical progress with lead candidate mavorixafor across multiple rare disease indications

X4 Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference

BOSTON, April 07, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will present a corporate overview at the 20th Annual …

X4 Pharmaceuticals Announces $55.0 Million At-the-Market Private Placement Financing

BOSTON, March 19, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it has agreed to sell an aggregate of 6,321,837 shares of its co…
Show more

X4 Pharmaceuticals Blogs

X4 Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 3, 2021

BOSTON , July 22, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the second quarter

X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences

X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences Content Import Mon, 05/17/2021 - 08:01 X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences May 17, 2021 This release is a backfill from a News Wire …

X4 Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 6, 2021

X4 Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 6, 2021 Content Import Thu, 04/22/2021 - 08:01 X4 Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 6, 2021 …

X4 Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference

X4 Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference Content Import Tue, 11/10/2020 - 08:02 X4 Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference November 10, 2020 This release is a backfill from a News Wire …

X4 Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

WHIM Phase 2 data published in ‘Blood’ - the Official Journal of the American Society of Hematology Granted Fast Track Designation by FDA for mavorixafor in WHIM syndrome Key leadership appointments including CSO and Board Director Conference call today at 8:30 a.m. ET BOSTON , Nov.

X4 Pharmaceuticals Appoints Art Taveras, Ph.D., as Chief Scientific Officer

CAMBRIDGE, Mass. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced the appointment of Art Taveras , Ph.D., as Chief Scientific
Show more

X4 Pharmaceuticals Frequently Asked Questions

  • When was X4 Pharmaceuticals founded?

    X4 Pharmaceuticals was founded in 2012.

  • Who are X4 Pharmaceuticals key executives?

    X4 Pharmaceuticals's key executives are Paula Ragan, Adam Mostafa and Art Taveras.

  • How many employees does X4 Pharmaceuticals have?

    X4 Pharmaceuticals has 80 employees.

  • Who are X4 Pharmaceuticals competitors?

    Competitors of X4 Pharmaceuticals include Acepodia, TSH Biopharm and Sprint Bioscience.

  • Where is X4 Pharmaceuticals headquarters?

    X4 Pharmaceuticals headquarters is located at 955 Massachusetts Ave, Cambridge.

  • Where are X4 Pharmaceuticals offices?

    X4 Pharmaceuticals has offices in Cambridge and Wien.

  • How many offices does X4 Pharmaceuticals have?

    X4 Pharmaceuticals has 2 offices.